PHOTODYNAMIC THERAPY MARKET ANALYSIS

Photodynamic Therapy Market, By Product Type (Photosensitizer Drugs (Porphyrin Derivative (PD) ( Hematoporphyrin Derivative (HpD), Benzoporphyrin Derivative (BPD), Texaphyrins, Others), Aminolevulinic acid (ALA), Chlorins, Others), Photodynamic Therapy Devices (Disposable Fiber Optic Light Delivery Devices (DFOLDD) and Diode Laser)), By Light Source (Lasers, Light Emitting Diodes (LEDs), Lamps, Others), By Application (Cancer, Actinic Keratosis (AK), Psoriasis, Acne, Others), By End User (Hospitals, Cancer Treatment Centers, Cosmetic and Dermatology Clinics, Others), By Geography (North America, Latin America, Europe, Asia Pacific, Middle East & Africa)

Global Photodynamic Therapy Market- Recent Developments

New Product Approvals

On July 5, 2023, the FDA had granted orphan drug designation to padeliporfin vascular targeted photodynamic therapy (VTP) for use as a potential therapeutic option in patients with locally advanced pancreatic cancer
On February 1, 2023, Bausch + Lomb Corporation, a leading global eye health company dedicated to help people see better to live better, and Modulight Corporation, a biomedical laser company, announced that the U.S. Food and Drug Administration (FDA) had approved the ML6710i photodynamic laser for equivalent use with Bausch + Lomb’s VISUDYNE (verteporfin for injection) photodynamic therapy (PDT) for the treatment of patients with predominantly classic subfoveal choroidal neovascularization, or the creation of abnormal choroidal blood vessels, due to Age-related Macular Degeneration (AMD).
On January 12, 2023, Biofrontera AG, an international biopharmaceutical company, announced that its wholly owned subsidiary Biofrontera Bioscience GmbH had received a notice of allowance for the application "Photodynamic therapy comprising two light exposures at different wavelengths" (US Appl. No. 17/269,816) by the U.S. patent office USPTO. This patent protects a number of innovations relating a new illumination method to treat dermatological skin diseases with Photodynamic Therapy (PDT).

Acquisition and Partnerships

On August 13, 2023, ImPact Biotech, a leader in photodynamic therapy, announced an agreement with Maastricht University to collaborate in research focused on eye treatment to arrest the progression of the severe eye disease Pathological Myopia, also known as Myopic Macular Degeneration (MMD). The project will use ImPact’s Padeliporfin Vascular targeted photodynamic therapy (VTP) therapy platform.
In September 2022, Quest PharmaTech Inc., a biotech company, announced the sale of its ownership interest in Bioceltran Co., Ltd. for a sum of US$ 300, 0000, together with the return and cancellation of the technology license for Photodynamic Therapy (PDT).
In January 2021, Olympus Corporation, a manufacturer of optics and reprography products, announced that it had entered into an agreement to acquire Quest Photonic Devices B.V., a medical device company, for up to US$ 52.7 million including milestone payments to strengthen its surgical endoscopy capabilities.